Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › KS › LENEXA › MAWD PATHOLOGY GROUP PA

MAWD PATHOLOGY GROUP PA

NPI: 1033108519 · LENEXA, KS 66215 · Clinical Medical Laboratory · NPI assigned 10/18/2005

$5.96M
Total Medicaid Paid
215,291
Total Claims
180,548
Beneficiaries
37
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialWILSON, JEFF (GENERAL MANAGER)
NPI Enumeration Date10/18/2005

Related Entities

Other providers sharing the same authorized official: WILSON, JEFF

ProviderCityStateTotal Paid
OBSTETRICAL GYNECOLOGICAL ASSOCIATES OF DES MOINES PLC DES MOINES IA $825K
MAWD PATHOLOGY PARTNERS PA LENEXA KS $299K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 10,883 $237K
2019 23,140 $584K
2020 43,485 $1.18M
2021 45,683 $1.36M
2022 33,926 $945K
2023 31,077 $837K
2024 27,097 $821K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 36,549 22,309 $1.25M
88305 Level IV - Surgical pathology, gross and microscopic examination 17,485 16,041 $922K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 31,237 28,846 $823K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 31,165 28,753 $820K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 25,247 23,264 $486K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 18,045 16,982 $462K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 11,256 9,839 $247K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 16,154 10,023 $227K
88307 2,485 2,404 $165K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 3,161 2,312 $123K
88142 8,039 7,155 $109K
87481 1,981 1,375 $49K
88141 2,943 2,776 $46K
88342 1,113 1,065 $42K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 1,295 818 $42K
88312 1,458 1,358 $32K
81513 321 306 $29K
87511 922 863 $19K
88304 1,457 1,410 $18K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 384 380 $17K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 972 718 $16K
87563 339 302 $7K
88300 268 268 $6K
88313 87 85 $2K
81514 25 24 $2K
87529 40 39 $1K
87086 Culture, bacterial; quantitative colony count, urine 181 177 $1K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision 433 420 $1K
88302 122 119 $936.34
88341 21 18 $858.62
88112 27 24 $684.47
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test 13 12 $224.56
86696 13 13 $217.58
86695 13 13 $132.30
85060 13 12 $118.40
87186 13 12 $93.62
87625 14 13 $0.00